GLP-1 agonists
Background
- Synthetic glucagon-like peptide-1 (GLP-1) receptor agonists
- Released by L-cells of the small intestine in response to the presence of nutrients
- Stimulate insulin release from pancreatic islet cells. It does this by stimulating glucose-dependent insulin release in the islet cells of the pancreas
- Slows gastric emptying times
- Increases satiety, which decreases drive for food intake
GLP-1 Agonist Types
Short Acting | Dose |
---|---|
Exenatide (Byetta) | 5-10 mcg SC bid |
Liraglutide (Victoza, Saxenda) | 0.6-1.8 mg SC daily |
Long Acting | |
Exenatide (Bydureon) | 2 mg SC qwk |
Albiglutide (Tanzeum) | 30-50 mg SC qwk |
Dulaglutide (Trulicity) | 0.75-1.5 mg qwk |
- Lixisenatide (Lyxumia, Adlyxin)
- Semaglutide (Ozempic, Rybelsus, Wegovy)
- Tirzepatide^ (Mounjaro, Zepbound)
^Dual GLP-1 and GIP agonist
Indication
- Diabetes Mellitus, Type 2
Adverse Reactions
- Nausea, vomiting, diarrhea
- Acute pancreatitis
- Exenatide should not be used in patients with creatinine clearance below 30mL/min
- Should not be used if personal of family history of medullary thyroid cancer or MEN 2A/2B